KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Revenue (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Revenue for 11 consecutive years, with $7.5 million as the latest value for Q1 2025.

  • Quarterly Revenue changed N/A to $7.5 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.5 million for FY2025, N/A changed from the prior year.
  • Revenue for Q1 2025 was $7.5 million at Xenon Pharmaceuticals, up from $132000.0 in the prior quarter.
  • The five-year high for Revenue was $8.8 million in Q1 2022, with the low at $132000.0 in Q3 2022.
  • Average Revenue over 3 years is $4.0 million, with a median of $4.0 million recorded in 2021.
  • Peak annual rise in Revenue hit 101.15% in 2022, while the deepest fall reached 97.07% in 2022.
  • Over 3 years, Revenue stood at $3.7 million in 2021, then crashed by 96.47% to $132000.0 in 2022, then skyrocketed by 5581.82% to $7.5 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $7.5 million, $132000.0, and $536000.0 for Q1 2025, Q3 2022, and Q2 2022 respectively.